Spantide I
| Code | Size | Price |
|---|
| TAR-T20413-25mg | 25mg | £765.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Spantide antagonizes both bombesin & substance P. It is also tachykinin receptor antagonist.
CAS:
91224-37-2
Formula:
C75H108N20O13
Molecular Weight:
1497.816
Purity:
0.98
SMILES:
CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CCCNC(N)=N)C(N)=O
References
1. Tan-No K, Sakurada T, Yamada T, Sakurada S, Kisara K. Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice. Neuropeptides. 1995 Nov;29(5):293-9. PubMed PMID: 8587665.
2. Wiesenfeld-Hallin Z, Xu XJ, Kristensson K, H?kanson R, Feng DM, Folkers K. Antinociceptive and substance P antagonistic effects of intrathecally injected spantide II in rat: no signs of motor impairment or neurotoxicity. Regul Pept. 1990 Jun;29(1):1-11. PubMed PMID: 1697080.
3. Yanagisawa M, Otsuka M. Pharmacological profile of a tachykinin antagonist, spantide, as examined on rat spinal motoneurones. Br J Pharmacol. 1990 Aug;100(4):711-6. PubMed PMID: 1698496; PubMed Central PMCID: PMC1917608.
4. Beding-Barnekow B, Leander S, Ohlin M, Ninn-Pedersen K, Alkner U, H?kanson R. Systemic and intraocular uptake of spantide, a tachykinin antagonist, following topical application to the rabbit eye. Exp Eye Res. 1990 Jan;50(1):21-6. PubMed PMID: 1689665.